LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.41 2.55

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.33

Max

2.44

Belangrijke statistieken
By Trading Economics
Inkomsten	-27M -17M
EPS	-0.125
Winstmarge	-2,366.017
Werknemers	23
EBITDA	-5.5M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+125.85% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-5M 478M
Vorige openingsprijs	-0.14
Vorige sluitingsprijs	2.41

Nieuwssentiment

By Acuity

50%

161 / 344 Rangschikking in Healthcare

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jun 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Belangrijke Marktbewegers

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Acquisities, Fusies, Overnames

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Marktinformatie

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Marktinformatie

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Marktinformatie

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Marktinformatie

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Marktinformatie

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Marktinformatie

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Acquisities, Fusies, Overnames

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Marktinformatie

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Marktinformatie

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Marktinformatie

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

125.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.33 USD 125.85%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

161 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.